AU2011353202A1

AU2011353202A1 - Release reagent for vitamin D

Info

Publication number: AU2011353202A1
Application number: AU2011353202A
Authority: AU
Inventors: Antonius Franciscus Maas; Michael Franciscus Wilhelmus Cornelis Martens; Franciscus Maria Anna Rosmalen; Leon Maria Jacobus Wilhelmus Swinkels
Original assignee: Future Diagnostics BV
Current assignee: Future Diagnostics BV
Priority date: 2010-12-28
Filing date: 2011-12-27
Publication date: 2013-07-11
Anticipated expiration: 2031-12-27
Also published as: AU2011353202B2; RU2013127156A; CA2821415A1; BR112013016352A2; WO2012091569A1; JP2014501392A; CN103282390A; KR20140019780A; JP2017083475A; CN108267602A; EP2635611B1; RU2579312C2; JP6138053B2; EP2635611A1; ES2614817T3; US10422805B2; CN108267602B; JP6560271B2; BR112013016352B1; US20140147935A1

Abstract

Disclosed is an invention in the field of conducting an immunoassay of 25(OH) vitamin D in blood or blood components, notably serum or plasma. The invention employs a perfluoro alkyl acid, or a salt thereof,to release 25(OH) vitamin D from vitamin D binding protein. Thereafter the binding protein comprising the 25-OH vitamin D is subjected to a competitive binding assay with a labeled vitamin D compound.

Description

WO 2012/091569 PCT/NL2011/050905 Title: RELEASE REAGENT FOR VITAMIN D Field of the invention The present invention pertains to an immunoassay method, including point-of-care tests, for assaying a sample of blood or blood 5 components for total vitamin D or Vitamin D metabolites, in particular 25 hydroxy vitamin D using an agent to release Vitamin D from endogenous binding proteins. Background of the invention 10 The substances referred to as "vitamin D" encompass a group of fat soluble prohormones, as well as metabolites and analogues thereof. The main forms in which vitamin D occurs in the body are vitamin D 2 (ergocalciferol) and vitamin D 3 (cholecalciferol). The latter is the endogenous form of vitamin 15 D, which humans can form in the skin under the influence of sunlight. The former is an exogenous form of vitamin D, taken up with food. In the US, Vitamin D2 is used as the pharmaceutical vitamin D supplement. Whilst vitamin D 2 and D 3 differ in the molecular structure of their side-chains, they share the same biological activity in being prohormones, 20 metabolized in two steps to, ultimately, 1,25 dihydroxy vitamin D (calcitriol, or 1,25 dihydroxy cholecalciferol). The preceding metabolite, 25-hydroxy vitamin D or calcidiol, results from conversion in the liver, and is considered the storage form of vitamin D in the body. Circulating vitamin D consists mainly of 25(OH)vitamin D3 and 25 25(OH)vitamin D2. Biologically, 25(OH)vitamin D2 is as effective as 25(OH)vitamin D3. The half-life of 25(OH)vitamin D2 in the circulation is shorter. For clinical practice the use of an 25(OH)vitamin D assay that WO 2012/091569 PCT/NL2011/050905 2 measures both 25(OH)vitamin D3 as well as 25(OH)vitamin D2 is recommended (1). Vitamin D has long been recognized as an important substance, the active form of which plays a role in the formation and maintenance of bone, as 5 well as in other processes in the human or animal body. Thus, it serves to increase the concentration of calcium in the bloodstream, by promoting absorption of calcium and phosphorus from food in the intestines, and re absorption of calcium in the kidneys; enabling normal mineralization of bone and preventing hypocalcemic tetany. It is also necessary for bone growth and 10 bone remodeling by osteoblasts and osteoclasts. Vitamin D deficiency results in impaired bone mineralization and leads to bone softening diseases, rickets in children and osteomalacia in adults, and possibly contributes to osteoporosis. In recent years it has been recognized that Vitamin D plays a 15 number of other roles in human health. It can modulate the immune function and reduce inflammation. It has also been suggested that Vitamin D may prevent colon, breast and ovarian cancer. Thus, it is of the essence for a person's or animal's health to have an adequate level of vitamin D. 20 Yet, excess of vitamin D (which may occur as a result of overdosing) is toxic. Some symptoms of vitamin D toxicity are hypercalcaemia (an elevated level of calcium in the blood) caused by increased intestinal calcium absorption. Vitamin D toxicity is known to be a cause of high blood pressure. Gastrointestinal symptoms of vitamin D toxicity can include anorexia, nausea, 25 and vomiting. These symptoms are often followed by polyuria (excessive production of urine), polydipsia (increased thirst), weakness, nervousness, pruritus (itch), and eventually renal failure. Clearly, it is important to be able to diagnose subjects for a possible vitamin D deficiency. It is also important, particularly for subjects that are on 30 vitamin D supplementation, to be able to test subjects for a potential excess of WO 2012/091569 PCT/NL2011/050905 3 vitamin D. In clinical practice, the serum level of 25-hydroxy-vitamin D is considered to be the primary indicator of the vitamin D status. (2). Almost all circulating 25(OH)-vitamin D in serum is bound by vitamin D binding protein (88%) and Albumin (12%). Vitamin D binding 5 protein (DBP) is an abundant protein, with a concentration of 250-400 mg/L of serum. Vitamin D is bound to DBP with a relatively high affinity, close to that of antibodies (5*108 M 4 ). An accurate measurement of the concentration of Vitamin D in serum requires the release of bound vitamin D from the DBP. 10 Early methods for the determination of Vitamin D included an extraction step using organic solvents such as acetonitrile. Other approaches have relied on dissociation of Vitamin D-DBP complex using a high or low pH (W02004/063704). Other methods rely on the competitive displacement of Vitamin D from endogenous binding proteins using ANS (US 7,482,162). 15 Recently methods including proteolytic digestion of DBP have been published (WO 2008/092917 Al). Armbruster has published a method for direct measurement of Vitamin D using displacement by hydroxylated aromatic carboxylic acid (WO 2003/023391). The method described by Kyriatsoulis relies on the release of Vitamin D from Vitamin-D binding protein by using a reagent 20 with a pH from 3.8 to 4.8 and 5-30% DMSO, a liquid organic amide and optionally 0.5-5% of a short chain alcohol. Kobold presented a method for the release based on a salt with a cation having a quaternary nitrogen based ion.EP2007/140962. US 2008/0182341 mentions stabilizing agents and capture ligands for use in assays measuring analyte concentrations. These stabilizing 25 agents are disclosed against the background of certain alkyl amino fluoro surfactants. The inventors suggest that this surfactant facilitates the measurement of free unbound analyte versus bound analyte by stabilizing the equilibrium. Fluorocarbon octanoic acid is mentioned as a potential hazardous substance.

WO 2012/091569 PCT/NL2011/050905 4 Background references on assaying Vitamin D include Hollis BW. Measuring 25-hydroxyvitamin D in a clinical environment: challenges and needs. Am J Clin Nutr. 2008 Aug;88(2):507S-510S; Holick MF. Vitamin D: extraskeletal health. Endocrinol Metab Clin North Am. 2010 Jun;39(2):381 5 400. Summary of the invention This invention, in one aspect, presents an in vitro method for the 10 qualitative assaying of blood or blood components for the presence of 25 hydroxy vitamin D, comprising: (a) adding to the sample a perfluoro alkyl acid with a carbon chain length of from 4 to 12 carbon atoms, or a salt thereof, in order to enable the release of Vitamin D from Vitamin D binding protein; 15 (b) optionally diluting the sample with a diluent; (c) subjecting the mixture to incubation with an immobilized binding protein, notably an anti-Vitamin D antibody; (d) contacting the sample with a conjugate of Vitamin D and a functional label that binds to the anti-Vitamin D antibody in a competitive 20 way (e) determining the concentration of labeled vitamin D compound bound to the binding protein In another aspect, the invention resides in a kit for conducting the foregoing method. 25 In yet another aspect the method can be used for "point-of-care" testing. The latter refers to testing at or near the site of patient care, i.e. rather than drawing blood samples and sending these to a diagnostic laboratory, a sample can be immediately introduced into a portable, preferably handheld device which is able to perform the assay in as limited a number of WO 2012/091569 PCT/NL2011/050905 5 steps as possible, and with as limited a number of manual operations as possible. Brief Description of the Drawings 5 Fig. 1 depicts a 25(OH)Vitamin D calibration curve. Fig. 2 presents a graph comparing results obtained with perfluorhexanoic (PFHxA) acid and with Perfluoroctanoic acid (PFOA) release. 10 Detailed Description of the Invention In a broad sense, the invention concerns the determination of Vitamin D in blood or blood components, notably serum or plasma, by an 15 immunoassay using a perfluoroalkyl acid or salt thereof with a carbon chain length of 4 to 12 to release Vitamin D from endogenous binding proteins. Conceivably, in the invention use can be made of perfluoroalkyl carboxylic acid or perfluoro sulfonic acid or salts thereof. In particular Perfluorhexanoic acid (PFHxA) or perfluoroctanoic acid (PFOA) can be used. 20 The assay generally involves (a) adding a diluent/assay buffer to sample (b) adding magnetic particles coated with anti-vitamin D antibody (c) incubating the sample for an amount of time (d) adding a conjugate of vitamin D and a functional label; 25 (e) determining the amount of the conjugate of vitamin D and the functional label bound to the antibody. Such samples can be drawn, in any manner known in the art, from a subject, particularly a human, in whose blood it is desired to assay the presence of 25-OH vitamin D.

WO 2012/091569 PCT/NL2011/050905 6 The sample preferably is diluted with an aqueous diluent. Preferably the diluent is an assay buffer. The dilution can take place before, during, or after the addition of the antibody. The sample diluent or assay buffer can be aqueous-based, and preferably will be a buffer solution. 5 Preferably, the buffered pH is in the range of from 6.0 to 8.0. Suitable diluents include, e.g. phosphate citrate buffer. The concentration of the perfluoro alkyl acid in the buffer should be 0. 1%-3%, preferably 0.5%. Suitable buffer solutions are customary in the art and do not require elucidation here. The perfluoro alkyl acid can be added in a separate manner, but 10 preferably is comprised in the sample diluent, preferably in the assay buffer. The sample is contacted with an anti- 25(OH)Vitamin D antibody The latter can be added to the sample, or the sample can be transferred to a reaction vial containing the binding protein. Antibodies for vitamin D are known in the art, and are widely used 15 in the existing immunoassays for vitamin D. These same antibodies, as well as other binding proteins, can be used in the present invention as well. E.g., in the place of an antibody for Vitamin D an antibody fragment can be used such as produced with phage display technology. Suitable antibodies can be monoclonal or polyclonal antibodies. They can be obtained in known manner, 20 e.g. polyclonal goat anti-vitamin D, polyclonal rabbit anti-vitamin D, or any other suitable antibody for vitamin D as known in the art from application in immunoassays for vitamin D. Suitable antibodies are known, e.g. from the following references: Hollis, Clin.Chem 31/11, 1815-1819 (1985); Hollis, Clin.Chem 39/3, 529-533 (1993). 25 The antibodies as used are preferably immobilized. They are preferably used in a particulate form comprising solid carriers. Typically, the antibody is coated on a solid phase, e.g. on a microtiter plate. In a preferred embodiment, the antibodies are coated onto magnetic particles, which facilitates their separation in a magnetic field.

WO 2012/091569 PCT/NL2011/050905 7 After addition of the antibody, the sample is allowed to incubate. The required time will depend on circumstances such as the concentration of the reagents, the type of binding protein, and conditions during incubation, e.g. shaking and temperature. Generally, the incubation time will be in a 5 range of from 10 seconds to several hours, preferably 1 minute to 1 hour. For automated platforms, short incubation times (10 seconds to 10 minutes, preferably 30 seconds to 30 minutes) are preferred. After the first incubation period, a conjugate of vitamin D with a functional label is added. Numerous labeled compounds are known that are 10 capable of serving as competitive binding antigens in immunoassays for the determination of vitamin D. Typical labels are radiolabels, fluorescent labels, luminescent labels, biotin labels, gold labels, enzyme labels. Competitive binding assays are known to the skilled person, and do not require elucidation, notably since this part of the method of the invention can be carried out using 15 any label known to be suitable for the determination of vitamin D. Labels that can be used are, inter alia, those disclosed in the foregoing references on existing vitamin D immunoassays. With the label allowing measuring a concentration, as a result, the concentration of vitamin D in the sample is determined. It will be understood 20 that the interpretation of the values measured, is determined by a calibration measurement, i.e. by the response - in the same assay - of calibrators. The calibration for the assay of the invention can be done by providing calibrators comprising a predetermined concentration of 25-OH vitamin D. The concentration of Vitamin D in the calibrators is preferably 25 determined using an LC-MS-MS method. The invention, in another aspect, presents a product in the form of an immunoassay for the determination of 25-OH vitamin D in blood or blood components, wherein the assay makes use of a method according to any one of preceding embodiments. More particularly, such a product will be provided in 30 the form of a kit for conducting the immunoassay. Such a kit may comprise the WO 2012/091569 PCT/NL2011/050905 8 loose reagents involved, i.e. the antibody, the labeled vitamin D compound and the diluents/assay buffer. These reagents can be provided separately, and thus form a kit only upon their use in the assay of the invention. Preferably, the reagents are provided together, preferably packaged together, as one kit of 5 parts. The kit optionally comprises a container for a sample of blood or blood components, but as is customary this may also be provided separately. Typically a kit comprises a binder immobilized on a solid phase and a separate conjugated vitamin D. Other kit components will depend, as is customary in the art, on the label chosen, as different labels may require different reagents. 10 It is to be understood that the invention is not limited to the embodiments and formulae as described hereinbefore. It is also to be understood that in the claims the word "comprising" does not exclude other elements or steps. Where an indefinite or definite article is used when referring to a singular noun e.g. "a" or "an", "the", this includes a plural of that 15 noun unless something else is specifically stated. The invention will be illustrated with reference to the following, non limiting Example and the accompanying non-limiting Figures. Example 20 Measurement of Vitamin D The assay was performed using an automated platform. To 15 gl of sample 255 gl of sample diluent/assay buffer was added. An aliquot of 100 l of the diluted sample was transferred to a second incubation well. A volume of 50 l of magnetic particles coated with monoclonal antibody was added to the 25 diluted sample and incubated for 45 minutes at 37 0 C. Subsequently 50 l of a solution biotinylated Vitamin D was added and incubated for 7 minutes at 37 'C. Then 50 l of a solution streptavidin-Acridinium ester was added and again incubated for 7 minutes at 37 'C. After magnetic separation of bound and free biotinylated Vitamin D, the bound acridinium ester was quantified. 30 WO 2012/091569 PCT/NL2011/050905 9 Materials Paramagnetic particles Magnetic particles (Invitrogen, M280 tosyl activated, 2.8 gm) were coated with a polyclonal antibody against Mouse IgG 5 (5 gg/mg of magnetic particles). The particles were coated on a roller at a concentration of 0.5 mg/ml in 0.01M PBS, 0.138M NaCl of pH 7.4 during 16 hours. Finally particles were blocked with 0.05M Tris / 0.05% BSA containing 0.l1% Proclin-950. The particles were coated during 16 hrs at 37 0 C with a second layer of anti-Vitamin-D monoclonal antibody at a concentration of 0.4 10 gg/mg particles. The sample diluent consisted of 0.1M TRIS buffer of pH 8.0 containing 0.05% BSA and 0.5% PFOA. 15 The conjugate (i.e. the labeled vitamin D compound) is a biotinylated Vitamin-D. The conjugate was presented at a concentration of 0.5 ng/ml in a 0.1M Tris buffer of pH 8.0 containing 0.05% Bovine Serum Albumin. Protocol 20 To 15 gl of sample 255 l of sample diluent/assay buffer was added. An aliquot of 100 gl of the diluted sample was transferred to a second incubation well. A volume of 50 gl of magnetic particles coated with monoclonal antibody was added to the diluted sample and incubated for 45 25 minutes at 37 0 C. Subsequently 50 gl of a solution biotinylated Vitamin D was added and incubated for 7 minutes at 37 0 C. Then 50 l of a solution streptavidin-Acridinium ester was added and again incubated for 7 minutes at 37 0 C. After magnetic separation of bound and free biotinylated Vitamin D, the bound acridinium ester was quantified. A chemiluminescent signal was 30 generated by addition of trigger reagent. The signal generated in the cuvette is WO 2012/091569 PCT/NL2011/050905 10 inversely proportional to the concentration of 25 (OH)Vitamin D in the sample or calibrator. The concentration of 25(OH) vitamin D in the original sample can be calculated by comparing the signal of unknowns with the response of calibrators. 5 Results In the table below, and in Fig. 1, a calibration curve is shown. 25(OH)Vitamin D3 calibrators were prepared in Vitamin D-free serum and 10 ranged from 0-136 ng/ml. Biotinylated 25(OH)Vitamin D is displaced to a level of 7% at 136 ng/ml. A set of samples was measured using perfluoroctanoic acid release and with perfluorhexanoic acid release. Results correlate very well (r = 0.990) 15 indicating that both compounds can be used (Fig 2). Table Table 1. 25(OH)Vitamin D calibration curve. 20 Standard curve St 0 St A St B St C St D St E dose (ng/mL) 0 4.1 13.5 24.9 52.1 136 RLU (1) 733227 618731 432378 254588 105251 41737 RLU (2) 754974 637612 422703 228484 106879 41870 RLU mean 744101 628172 427541 241536 106065 41804 RLU SD 15377 13351 6841 18458 1151 94 RLU %CV 2.1% 2.1% 1.6% 7.6% 1.1% 0.2% Binding % 100.0% 84.4% 57.5% 32.5% 14.3% 5.6%

Claims

1. A method for the qualitative in vitro assaying of blood or blood components for the presence of 25-hydroxy vitamin D, comprising: (a) adding to the sample a perfluoro alkyl acid with a carbon chain length of from 4 to 12 carbon atoms, or a salt thereof; 5 (b) optionally diluting the sample with a diluent; (c) subjecting the mixture to incubation with an anti-Vitamin D antibody; (d) contacting the sample with a conjugate of Vitamin D and a functional label that binds to the anti-Vitamin D antibody in a competitive 10 way; (e) determining the concentration of labeled vitamin D compound bound to the binding protein

2. A method according to claim 1, wherein the perfluoro alkyl acid is selected from the group consisting of perfluoro hexanoic acid, perfluoro 15 octanoic acid, and mixtures thereof.

3. A method according to claim 1 or 2, wherein the perfluoro alkyl acid is comprised in the diluent.

4. A method according to any one of the preceding claims, wherein the sample is diluted before incubation. 20

5. A method according to any one of the preceding claims, wherein the sample is human serum or plasma.

6. A method according to any one of the preceding claims, wherein the binding protein is provided in a form coated on magnetic particles.

7. A method according to any one of the preceding claims, wherein the 25 functional label is selected from the group consisting of radiolabels, fluorescent labels, luminescent labels, biotin labels, gold labels, enzyme labels. WO 2012/091569 PCT/NL2011/050905 12

8. A method according to any one of the preceding claims, wherein the concentration is determined with reference to a calibrator concentration for total 25-OH vitamin D.

9. A method according to any one of the preceding claims, wherein the 5 the perfluoro octanoic acid, or the derivative thereof, is selected from the group consisting of perfluoro octanoic acid, perfluoro octanoic acid ammonium salt, and perfluoro octane sulfonate.

10. An immunoassay for the determination of 25-OH vitamin D in blood or blood components, wherein the assay makes use of a method according to 10 any one of the preceding claims.

11. A kit for conducting an immunoassay using the method of any one of the claims 1-10, the kit comprising an antibody specific for 25-OH vitamin D immobilized on a solid phase, and a conjugate of Vitamin D and a functional label. WO 2012/091569 PCT/NL2011/050905 1/2 800000 U) 600000 0 0 u) 400000 200000 0-.................. ......... ......... .... 0.01 0.1 1 10 100 1000 25(OH)Vitamin D ng/ml Fig. 1 SUBSTITUTE SHEET (RULE 26) WO 2012/091569 PCT/NL2011/050905 2/2 Scatter Plot with Passing & Bablok Fit 60 50 40' r) 20 N1 30 U) 0 CD 00 Identity PFO Passing & Bablok () fit I (0.82 + 0.87x) 10. r=0. 990 0 0 10 20 30 40 50 60 PFOA release 25(OH)VitD ng/ml Fig. 2 SUBSTITUTE SHEET (RULE 26)